International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2025
July 8 and 9
Welcome
We are pleased to announce that the 16th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place 8-9 July 2025 as a virtual meeting.
This abstract-driven workshop has been the leading annual meeting in the tuberculosis (TB) pharmacology field since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for presentation and discussion of the latest scientific developments in the TB pharmacology field.
If you work in the field of TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, PhD students; and representatives from regulatory or non-governmental organizations active in the TB-field.
The program consists of oral presentations that will be put in perspective, with a translation to clinical care where possible, by selected experts at the end of each workshop session. In addition there will be e-poster abstract presentations. The workshop is informal in setting and is meant to be interactive.
We look forward to seeing you virtually this July!
On behalf of the Organizing Committee,
Virtual Meeting, 8-9 July, 2025
DRAFT AGENDA
| CET | EDT | ||
| DAY 1 Tuesday, July 8 | |||
| 3:00 PM | 9:00 AM | Opening of the workshop | Donna Setzer, Charles Peloquin & Rob Aarnoutse |
| Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | |||
| Chairs: Ulrika Simonsson & Jerry Nedelman | |||
| 3:05 PM | 9:05 AM | Pretomanid dosing and pharmacokinetics in North American patients with tuberculosis, 2019-2024 | Nicole Maranchick |
| 3:20 PM | 9:20 AM | Semi-mechanistic population pharmacokinetic modelling of the novel antituberculosis drug TBAJ-876 and its metabolite M3 in healthy volunteers | Jose Miguel Calderin Miranda |
| 3:35 PM | 9:35 AM | Drug interaction potential of sutezolid when combined with bedaquiline, delamanid and moxifloxacin in patients with pulmonary tuberculosis | Ombeni Chimbe |
| 3:50 PM | 9:50 AM | Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentrations of rifampicin | Arti Shrivas |
| 4:05 PM | 10:05 AM | Rapporteur session | |
| 4:30 PM | 10:30 PM | Coffee Break | |
| Session 2 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB meningitis) | |||
| Chairs: Christine Sekaggya & Rob Aarnoutse | |||
| 4:45 PM | 10:45 AM | High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trial | Rovina Ruslami |
| 5:00 PM | 11:00 AM | Beyond rifampin: evaluating rifapentine and rifabutin as alternative CNS-targeting treatments for TB meningitis in a murine model | Xueyi Chen |
| 5:15 PM | 11:15 AM | Bedaquiline central nervous system exposure in a rabbit model of tuberculous meningitis | Sean Wasserman |
| 5:30 PM | 11:30 AM | Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB | Caryn Upton |
| 5:45 PM | 11:45 PM | Rapporteur session | |
| 6:10 PM | 12:10 PM | Coffee Break | |
| Session 3 Clinical TB pharmacology flash talks | |||
| Chair: Eric Nuermberger | |||
| 6:25 PM | 12:25 PM | Kanamycin Otoxicity in Drug Resistance Tuberculosis: A Drug Use Evaluation Study | Achdi Kurnia |
| 6:30 PM | 12:30 PM | Need for Healthcare Provider Education in Tuberculosis Patient Care | Summer Walker |
| 6:35 PM | 12:35 PM | Quantitation of Plasma Bedaquiline Concentrations in Indian MDR-TB Patients Using Liquid Chromatography-Tandem Mass Spectrometry | Rohan Lokhande |
| 6:40 PM | 12:40 PM | Pretomanid exposure is not increased by severely impaired renal function | Jerry Nedelman |
| 6:45 PM | 12:45 PM | End of day 1 | |
| DAY 2 Wednesday, July 9 | |||
| 3:00 PM | 9:00 AM | Recap of the first day and introduction to the second day | |
| Session 4 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB in pregnancy, lactation and NTM disease) | |||
| Chairs: Caitlin Reed & Charles Peloquin | |||
| 3:05 PM | 9:05 AM | Pharmacokinetics and safety of clofazimine in women treated for rifampicin-resistant tuberculosis during pregnancy and the postpartum period | Jennifer Hughes |
| 3:20 PM | 9:20 AM | Population pharmacokinetic analysis of levofloxacin in breast milk among patients with rifampicin-resistant tuberculosis | Sharon Sawe |
| 3:35 PM | 9:35 AM | Azithromycin exposure and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial infections | Michael Rodgers |
| 3:50 PM | 9:50 AM | Rapporteur session | |
| 4:35 PM | 10:35 AM | Coffee Break | |
| Session 5 Approaches and tools in TB drug development and optimization and in treatment of patients | |||
| Chairs: Eric Nuermberger & Christine Sekaggya | |||
| 4:30 PM | 10:30 AM | Preclinical drug evaluation based on “pathogen health”: drug-specific M. tuberculosis physiologic injury and adaption in ex vivo caseum | Jo Hendrix |
| 4:45 PM | 10:45 AM | Development of an Antitubercular Drug Proficiency Testing Program | Raymond Cha |
| 5:00 PM | 11:00 AM | Development of an expert-based drug-drug interaction source to facilitate management of co-medications in patients with tuberculosis | David Burger |
| 5:15 PM | 11:15 AM | Comparison of salivary and serum levels of isoniazid, rifampicin and pyrazinamide in patients with tuberculosis | Samiksha Ghimire |
| 5:30 PM | 11:30 AM | Saliva pharmacokinetic population modelling and simulation of linezolid in multi-drug resistant tuberculosis | Anh Thi Nguyen |
| 5:45 PM | 11:45 AM | Rapporteur session | |
| 6:10 PM | 12:10 PM | Coffee Break | |
| Session 6 Clinical TB pharmacology flash talks | |||
| Chair: Caitlin Reed | |||
| 6:25 PM | 12:25 PM | Bedaquiline Dosing and Pharmacokinetics in North American Patients with Tuberculosis, 2019-2024 | Nicole Maranchick |
| 6:30 PM | 12:30 PM | Approaches and tools in TB drug development and optimization: Therapeutic Drug Monitoring, pharmacogenetics, biomarkers, etc; innovations and applications | Ronald Arnold Magoba |
| 6:35 PM | 12:35 PM | Optimizing the quantitation of rifampicin and pretomanid in human plasma by liquid chromatography tandem mass spectrometry | Lauren Hill |
| 6:40 PM | 12:40 AM | End of day 2 and of the workshop | Donna Setzer, Charles Peloquin & Rob Aarnoutse |
WHO SHOULD ATTEND?
The target audience of this workshop- preclinical and clinical pharmacology researchers from academia and industry
- medical doctors
- pharmacists and pharmacologists involved in clinical management of TB patients
- PhD students
- representatives from regulatory or non-governmental organizations active in the TB-field.
- nurses
- laboratorians
- others working in TB